John H. Powers, III, MD

Director of Collaborative Research
Leidos Biomedical Research

Disclosure(s): Arrevus: Advisor/Consultant; Eicos: Advisor/Consultant; Evofem: Advisor/Consultant; Eyecheck: Advisor/Consultant; Gilead: Advisor/Consultant; GlaxoSmithKline: Advisor/Consultant; OPKO: Advisor/Consultant; Resolve: Advisor/Consultant; Romark: Advisor/Consultant; SpineBioPharma: Advisor/Consultant; UTIlity: Advisor/Consultant; Vir: Advisor/Consultant

Poster(s):

• 273 - Emergence of the SARS-CoV-2 Omicron Variant in the Pragmatic Assessment of Influenza Vaccine Effectiveness in the Department of Defense (PAIVED) Study
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 1047 - Asymptomatic SARS-CoV-2 Infections, BNT162b2 mRNA COVID 19 Vaccine-Related Symptoms, and Correlates of Immunity in Post-Vaccination Breakthrough Infections in the Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 1830 - Epidemiology of Recurrent Bacterial Bloodstream Infections in the US Military Health System
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1831 - Longitudinal Changes in Antimicrobial-resistant Bacterial Bloodstream Infections in the US Military Health System from 2010-2019
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET